Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 261 results for "Byetta"

Human medicines European public assessment report (EPAR): By...

This is a summary of the European public assessment report (EPAR) for Byetta. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and ... European Medicines Agency, 1 month ago
GLP-1 Receptor Agonists in T2DM -- Guidelines vs Practice General Medicine eJournal, 1 month ago

1 images for "Byetta"

PRWeb, 1 week ago

Byetta Lawsuit News: Bernstein Liebhard LLP Notes British Columbia's Recent Decision to Discontinue Incretin Mimetic Drug Coverage from PharmaCare Program

Healthcare regulators in British Columbia have stopped patient coverage of a diabetes drug now involved in hundreds of Byetta lawsuits ( as well as several other medications, Bernstein Liebhard LLP reports. According ...
 Digital Journal1 week ago Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Establishes Deadlines Pertaining to Discovery, Bernstein Liebhard LLP Reports  Digital Journal1 month ago

Byetta Lawsuit News: New Order Establishes Deposition Protocol For Federal Incretin Mimetics Litigation, Bernstein Liebhard LLP Reports

Byetta lawsuits ( and legal claims involving other incretin mimetic Type 2 diabetes drugs, such as Januvia and Victoza, continue to move forward in a federal multidistrict litigation now underway in U.S. District Court, ...
 Digital Journal1 week ago
PR Newswire

Legal-Bay Lawsuit Settlement Funding Reports Increase In Number of Filed Cases Involving Byetta (Exenatide) Litigation

Pre-Settlement Case Funding Firm announces new program focus for plaintiffs of Byetta, as well as Actos, Januvia, and
 RCL Advisors1 month ago Takeda Pharmaceutical Co. Ltd. Release: Lawsuit Settlement Funding Reports $9 Billion In The First Actos (Pioglitazone) Settlement  BioSpace2 months ago
Jutia Group

Stock Update: Bristol-Myers Squibb Company (NYSE:BMY) U.S. FDA Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy

[Business Wire] Bristol-Myers Squibb Company and Pfizer Inc. today announced the U.S. Food and Drug Administration has approved a Supplemental New Drug Application for Eliquis for the treatment of DVT and PE, and for the reduction in the risk of ...
 Jutia Group1 day ago Stock Update (NYSE:BMY): Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis® (apixaban) at the ESC Congress 2014  Jutia Group3 days ago Bristol-Myers Squibb Company (NYSE:BMY) | Leica Biosystems and Bristol-Myers Squibb Enter Into a Development and Commercialization Collaboration for Companion Diagnostics that Support Targeted Therapies  Jutia Group2 weeks ago Second Quarter & Half Year Results 2014  TrustNet3 weeks ago

GBK Presents a Luxury Gift Lounge Honoring the Nominees and Presenters of the 2014 Emmy® Awards - August 22nd and 23rd - Beverly Hills

(Date:8/19/2014)... The elegant bamboo floorings from ... houses in an environmentally conscious way with the company's ... and have an aluminum oxide finish to help resist ... high-traffic areas. , Recently, the company has ...
 Bio-Medicine3 days ago

Lawsuit Settlement News Website Reports Update on Risperdal Litigation Due to Increase of Filed Cases

PHILADELPHIA, Aug. 15, 2014 /PRNewswire/ -- MT Services LLC, A Lawsuit Settlement News Reporting Company, which operates a lawsuit help center:, announced today that there is ongoing litigation for victims of the ...
 TickerTech.com1 week ago Lawsuit Settlement News Reports Bad Pharmaceutical Drug Cases Are Ongoing While Funding For Cash Advances and Free Attorney Legal Consultations Are Available  RCL Advisors1 month ago

Biotech Stock Directory Update

( Newswire) staff:, a global news source covering leading sectors issues the updated biotech stock directory for August. The directory is part of the member's directory list including tech and ...
 InvestorIdeas.com1 week ago

Aegis Therapeutics, LLC Release: First Non-Injectable GLP-1 Analog For Type-2 Diabetes

) - Aegis announced today that it is offering an exclusive license to develop, commercialize, and sell its patented non-invasive exenatide metered nasal spray diabetes drug. Exenatide is a 39-amino acid synthetic peptide GLP-1 analog highly ...
 BioSpace2 weeks ago First Non-Injectable GLP-1 Analog for Type-2 Diabetes  4 Traders2 weeks ago
Pharma Letter

AstraZeneca (AZN) Beats on Q2 Earnings, Guidance Raised

AstraZeneca ( AZN ) reported second-quarter 2014 core earnings of $1.30 per American Depositary Share ( ADS ) beating the Zacks Consensus Estimate of $1.13. Earnings were also up 13% (at constant exchange rates or CER) year over year buoyed by ...
 Yahoo! Finance3 weeks ago AstraZeneca 2nd-qtr earnings leap, beating expectations  Pharma Letter3 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less